CureVac (CVAC) Projected to Post Quarterly Earnings on Wednesday

CureVac (NASDAQ:CVAC) will likely be releasing its earnings data before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.27 per share and revenue of $20.58 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

CureVac (NASDAQ:CVAC) last released its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The firm had revenue of $15.44 million for the quarter, compared to analysts’ expectations of $6.40 million. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Price Performance

Shares of CureVac stock opened at $3.23 on Wednesday. The firm has a market capitalization of $723.13 million, a PE ratio of 5.87 and a beta of 2.48. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. CureVac has a 12 month low of $2.22 and a 12 month high of $5.28. The business’s 50-day moving average price is $3.11 and its 200-day moving average price is $3.16.

Wall Street Analyst Weigh In

Separately, JMP Securities reiterated a “market outperform” rating and set a $16.00 price target on shares of CureVac in a research report on Friday, February 14th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.